Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR 주식 보고서

시가총액: US$2.7b

Arrowhead Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 3/6

Arrowhead Pharmaceuticals 의 총 주주 지분은 $339.0M 이고 총 부채는 $336.0M, 이는 부채 대 자기자본 비율을 99.1% 로 가져옵니다. 총자산과 총부채는 각각 $883.8M 및 $544.8M 입니다.

주요 정보

99.1%

부채 비율

US$336.03m

부채

이자 보상 비율n/a
현금US$434.47m
주식US$338.97m
총 부채US$544.79m
총 자산US$883.76m

최근 재무 상태 업데이트

Recent updates

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 12
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 17

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

재무 상태 분석

단기부채: ARWR 의 단기 자산 ( $450.1M )이 단기 부채( $96.7M ).

장기 부채: ARWR 의 단기 자산( $450.1M )이 장기 부채( $448.1M ).


부채 대 자본 내역 및 분석

부채 수준: ARWR 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: ARWR 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 99.1% 로 증가했습니다.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: ARWR 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 47 %의 역사적 비율로 계속 감소할 경우 ARWR 의 현금 활주로는 1년 미만입니다.


건강한 기업 발견하기